CSANZ Logo
CSANZ Logo
Welcome to the official website of the


CSANZ Logo
CSANZ Logo
Cardiac Society of Australia and New Zealand
CSANZ Logo


CSANZ Logo


CSANZ Logo

contact
links
want to join?
register
search the CSANZ website
search the CSANZ website
     







search the CSANZ website













CSANZ Directory

CSANZ Member Directory

CSANZ Guidelines

Practice Guidelines

Training and Competence

Meetings

What's On and Where

ASM Abstracts Online

News and Views

Newsletter - On the Pulse

Newsletter - CNWG

In the News

Affiliate News
Career Opportunities

Affiliate Member Area

Affiliate Calendar

Affiliate Discussion

Scholarships/ Fellowships

Working Groups


ASM Abstracts

DETERMINANTS OF HOSPITAL READMISSION WITH HEART FAILURE

S P Wright*, H Walsh, G Gamble, N Sharpe, R N Doughty

Dept of Medicine, University of Auckland, Auckland, New Zealand.

Background: Heart failure is characterised by frequent hospital readmissions, at the cost of ~1% of total annual healthcare expenditure. The role of clinical and socio-demographic features on readmission rates are uncertain. This study investigated determinants of time to first readmission after an index admission for heart failure.

Methods: Determinants of hospital readmission were studied in a prospectively identified cohort of 197 patients hospitalised for an exacerbation of HF. The cohort was recruited into a post-discharge interventional study which did not effect hospital readmission in the first 3 months. Determinants of readmission were determined using non-parametric univariate and multiple regression techniques.

Results: 197 patients were included: mean age 73 (SD 10.5), 60% male, 68% NYHA class 4; 55% had 1 or more prior admissions for heart failure, 79% were caucasian. The median time to first readmission was 65 days (IQR 25, 184). 13% of the cohort were readmitted within 2 weeks after the index admission. Factors associated with readmission in the first two weeks on included the number of previous admissions with HF; the dose of frusemide at discharge from index admission; LVEDD and LVESD. 38% of the cohort were re-admitted within 65 days. Factors associated with readmission within 65 days included number of previous admissions with HF and frusemide dose at discharge. Group allocation to usual care or the HF management intervention (follow-up in a dedicated hospital-based clinic) had no effect on readmission at 2 weeks (p=0.9) or 65 days (p=1.0). On multivariate analysis, factors associated with shorter time to readmission included the presence of angina; orthopnea or a raised JVP at previous discharge; and length of stay during the index admission.

Conclusion: Patients with HF who still have signs of peripheral congestion at the time of discharge and those with a long stay during their index admission are at high risk of readmission within the first 2 months after discharge. Clinical pathways in HF should target discharge planning to patients with prolonged hospital stays. The effects of increased primary-secondary care integration needs to be re-assessed in this group of patients at high risk of readmission.

[ Back to 48th ASM Abstract Index ]


Med-E-Serv